Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Aspirin and diet may fight cancer return

NCT ID NCT05036109

Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether taking daily aspirin and vitamin D, along with exercise and a low-fat diet, could help prevent colorectal cancer from returning in 16 patients who had no visible cancer but still had signs of cancer DNA in their blood. The goal was to see if these lifestyle changes could clear those DNA markers. While the approach is promising, it is not a cure and focuses on managing the risk of recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

16 people

The number who actually took part.

Started

Oct 2021

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years at the time of study entry * ECOG 0-1 * Histologically documented high-risk stage II, stage III, or stage IV colorectal adenocarcinoma with no evidence of disease following definitive local therapy (including surgical resection or ablation) * No radiographic evidence of disease by contrast enhanced CT chest/abdomen/pelvis * Presence of detectable ctDNA mutation that matches mutations found in tumor tissue * Completion of all standard of care adjuvant therapy * Platelet count \>50,000 * Ability to give informed consent * Ability to complete all questionnaires involved in study Exclusion Criteria: * Concurrent malignancy under active treatment * Known active gastrointestinal bleeding or peptic ulcer disease * Known hypersensitivity to vitamin D or aspirin * CrCl\<30 mL/min within 30 days of starting the intervention * Current usage of therapeutic anticoagulation (warfarin, Eliquis, Xarelto) * Inability to safely participate in physical activity in the opinion of the treating oncologist * Pregnant or nursing women. N.B.: urine pregnancy test will be administered as part of the screening process. * Persistent hypercalcemia or conditions predisposing to hypercalcemia (i.e., hyperparathyroidism) * Known symptomatic genitourinary stones

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colon cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm colorectal adenocarcinoma colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colon cancer Colorectal cancer

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.